News | January 28, 2025
Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr
Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024
Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies
EBITDA margins expand to 31.3%
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Subscribe To Our Newsletter & Stay Updated
